Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y14 receptor antagonist for inflammatory bowel disease therapy

This study demonstrates that computational repurposing successfully identifies DB07565 as a high-affinity P2Y₁₄R antagonist with therapeutic efficacy in IBD. Its established safety, oral stability, and optimized ADME/T properties position it as a clinically translatable candidate, underscoring the value of integrating SBVS and drug repurposing for accelerating anti-inflammatory drug discovery.